within Pharmacolibrary.Drugs.ATC.C;

model C02KX02
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.86,
    Cl             = 3.4 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 10 / 1000000,
    adminCount     = 1,
    Vd             = 0.019,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.011416666666666667,
    Tlag           = 10.200000000000001
  );

  annotation(Documentation(
    info ="<html><body><p>Ambrisentan is an endothelin receptor antagonist used primarily for the treatment of pulmonary arterial hypertension (PAH) to improve exercise capacity and delay clinical worsening. It is an orally active, selective endothelin type A (ETA) receptor antagonist and is currently approved for use in several countries.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in healthy adult subjects following single oral administration.</p><h4>References</h4><ol><li><p>Spence, R, et al., &amp; Boinpally, R (2010). Effect of steady-state ambrisentan on the pharmacokinetics of a single dose of the oral contraceptive norethindrone (norethisterone) 1 mg/ethinylestradiol 35 microg in healthy subjects: an open-label, single-sequence, single-centre study. <i>Clinical drug investigation</i> 30(5) 313–324. DOI:<a href=&quot;https://doi.org/10.2165/11534940-000000000-00000&quot;>10.2165/11534940-000000000-00000</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/20384387/&quot;>https://pubmed.ncbi.nlm.nih.gov/20384387</a></p></li><li><p>Buckley, MS, et al., &amp; Feldman, JP (2011). Pharmacokinetic evaluation of ambrisentan. <i>Expert opinion on drug metabolism &amp; toxicology</i> 7(3) 371–380. DOI:<a href=&quot;https://doi.org/10.1517/17425255.2011.557181&quot;>10.1517/17425255.2011.557181</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/21299444/&quot;>https://pubmed.ncbi.nlm.nih.gov/21299444</a></p></li><li><p>Walker, G, et al., &amp; Venitz, J (2009). The pharmacokinetics and pharmacodynamics of warfarin in combination with ambrisentan in healthy volunteers. <i>British journal of clinical pharmacology</i> 67(5) 527–534. DOI:<a href=&quot;https://doi.org/10.1111/j.1365-2125.2009.03384.x&quot;>10.1111/j.1365-2125.2009.03384.x</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/19552747/&quot;>https://pubmed.ncbi.nlm.nih.gov/19552747</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end C02KX02;
